Therefore, to determine whether the binding of mAb to Bi could recruit complement components, mediate inflammation, enhance ADCC effects, and exhibit immune-dependent cytotoxic effects, the activation of the complement system was assessed after treatment with Bi and mAb, which indicated a significant elevation of tumor and serum C3 levels in Bi + mAb-treated mice (Fig. 3A). This evidence concerns the gene C3 and neoplasm.